DK1213030T3 - Fremgangsmåde til fremstilling af biologiske produkter i protein-fri kultur - Google Patents

Fremgangsmåde til fremstilling af biologiske produkter i protein-fri kultur

Info

Publication number
DK1213030T3
DK1213030T3 DK01130212T DK01130212T DK1213030T3 DK 1213030 T3 DK1213030 T3 DK 1213030T3 DK 01130212 T DK01130212 T DK 01130212T DK 01130212 T DK01130212 T DK 01130212T DK 1213030 T3 DK1213030 T3 DK 1213030T3
Authority
DK
Denmark
Prior art keywords
viruses
viral
protein
preparation
producing
Prior art date
Application number
DK01130212T
Other languages
English (en)
Inventor
Wolfgang Mundt
Otfried Kistner
Noel Barret
Friedrich Dorner
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/487,046 external-priority patent/US5753489A/en
Priority claimed from US08/483,522 external-priority patent/US5756341A/en
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Application granted granted Critical
Publication of DK1213030T3 publication Critical patent/DK1213030T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK01130212T 1994-11-10 1995-11-10 Fremgangsmåde til fremstilling af biologiske produkter i protein-fri kultur DK1213030T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33876194A 1994-11-10 1994-11-10
US48722295A 1995-06-07 1995-06-07
US08/487,046 US5753489A (en) 1994-11-10 1995-06-07 Method for producing viruses and vaccines in serum-free culture
US08/483,522 US5756341A (en) 1994-11-10 1995-06-07 Method for controlling the infectivity of viruses
PCT/EP1995/004439 WO1996015231A2 (en) 1994-11-10 1995-11-10 Method for producing biologicals in protein-free culture

Publications (1)

Publication Number Publication Date
DK1213030T3 true DK1213030T3 (da) 2009-07-20

Family

ID=27502591

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95937888T DK0791055T3 (da) 1994-11-10 1995-11-10 Fremgangsmåde til fremstilling af biologiske produkter i proteinfri kultur
DK01130212T DK1213030T3 (da) 1994-11-10 1995-11-10 Fremgangsmåde til fremstilling af biologiske produkter i protein-fri kultur

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK95937888T DK0791055T3 (da) 1994-11-10 1995-11-10 Fremgangsmåde til fremstilling af biologiske produkter i proteinfri kultur

Country Status (10)

Country Link
EP (3) EP1213030B1 (da)
JP (1) JP3158157B2 (da)
AT (2) ATE429246T1 (da)
CA (2) CA2205015C (da)
DE (1) DE69535940D1 (da)
DK (2) DK0791055T3 (da)
ES (2) ES2323490T3 (da)
FI (1) FI121117B (da)
HK (1) HK1002285A1 (da)
WO (1) WO1996015231A2 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
DE19655440B4 (de) * 1996-04-01 2013-09-05 Novartis Vaccines And Diagnostics Gmbh Verfahren zur Herstellung eines Influenzaimpfstoffs
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
EP1482031B1 (en) 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US6110724A (en) * 1996-10-18 2000-08-29 The Research Foundation For Microbial Diseases Of Osaka University Rotavirus antigen, vaccine and diagnostic agent for rotavirus infections, and a method for producing the antigen
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
ATE330003T1 (de) * 1999-08-05 2006-07-15 Baxter Ag Rekombinanter stabiler zellklon, seine herstellung und verwendung
WO2001014517A1 (fr) * 1999-08-20 2001-03-01 Japan Science And Technology Corporation Procede et appareil de proliferation du virus de l'hepatite
ATE473272T1 (de) * 2000-03-03 2010-07-15 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
US6830917B2 (en) 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
US6855535B2 (en) 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
DK2287288T3 (da) 2002-07-09 2013-01-07 Baxter Int Medium frit for animalsk protein til dyrkning af celler
CN1692156B (zh) 2002-09-05 2011-05-11 巴法里安诺迪克有限公司 在无血清条件下培养原代细胞和扩增病毒的方法
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
EP1739167B1 (en) 2004-04-19 2015-08-12 DENKA SEIKEN Co., Ltd. Method of producing virus
CA2890962A1 (en) 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Decreasing potential iatrogenic risks associated with influenza vaccines
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006074524A1 (en) * 2005-01-14 2006-07-20 Robert Alexander Virus recovery medium, use thereof and viral diagnostic kit including same
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DK2368572T3 (da) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
CN101360820A (zh) 2006-01-04 2009-02-04 巴克斯特国际公司 无寡肽的细胞培养基
EP1982727A1 (en) * 2007-04-17 2008-10-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for purification of viral proteins
WO2008153366A2 (en) 2007-06-15 2008-12-18 Mogam Biotechnology Research Institute Method for manufacturing active recombinant blood coagulation factor ix
AU2009334512B2 (en) 2008-12-30 2014-04-24 Takeda Pharmaceutical Company Limited Method of enhancing cell growth using alkyl-amine-n-oxide (AANOx)
WO2010079081A1 (en) * 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
CA2760657A1 (en) * 2009-05-08 2010-11-11 Glaxosmithkline Biologicals S.A. Method for producing virus from cell culture involving homogenization
BR112012002151B1 (pt) 2009-07-31 2021-07-06 Baxalta GmbH método para expressar uma desintegrina e metaloproteinase com proteína de motivo trombospondina (adamts)
CN103025350A (zh) * 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
AU2015258263B2 (en) * 2010-05-21 2017-12-07 Seqirus UK Limited Influenza virus reassortment method
EP2591094B1 (en) 2010-07-08 2018-09-05 Baxalta GmbH Method of producing recombinant adamts13 in cell culture
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
ES2895173T3 (es) 2012-06-29 2022-02-17 Emd Millipore Corp Métodos para inactivar virus durante un proceso de purificación de proteínas
CN104755606B (zh) 2012-08-31 2019-04-12 阿尔伯达大学董事会 用于产生具有原代人肝细胞表型的细胞的方法和组合物
SG11201605146VA (en) 2013-12-30 2016-07-28 Baxalta GmbH A method of predicting a performance characteristic of a plant or yeast hydrolysate and its use
EP2966093A1 (en) 2014-07-07 2016-01-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use
EP3486316A4 (en) * 2016-07-15 2019-12-04 The Research Foundation for Microbial Diseases of Osaka University PROCESS FOR PRODUCING REASSURED INFLUENZA VIRUSES
KR101869010B1 (ko) 2016-09-09 2018-06-20 주식회사 포스코 이물 제거장치
KR20200040750A (ko) * 2017-08-28 2020-04-20 잇판사이단호진한다이비세이부쯔뵤우겐큐우카이 리소턴트 인플루엔자 바이러스의 단계적 작출 방법
WO2020004425A1 (ja) * 2018-06-27 2020-01-02 一般財団法人阪大微生物病研究会 インフルエンザウイルスの培養方法
RU2738404C1 (ru) * 2019-08-26 2020-12-11 Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" Способ инактивации культурального ротавируса человека

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445466B (sv) * 1977-12-01 1986-06-23 Wellcome Found Sett att foroka rotavirus in vitro
CA1122527A (en) * 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
US4500513A (en) 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
GB8300467D0 (en) * 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US5136019A (en) 1989-05-24 1992-08-04 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
AT393356B (de) * 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
AT393277B (de) 1990-01-04 1991-09-25 Immuno Ag Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen
JPH04228066A (ja) * 1990-10-23 1992-08-18 Rikagaku Kenkyusho 外来遺伝子発現用培養細胞
EP0531562A1 (de) 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen

Also Published As

Publication number Publication date
EP1213030B1 (en) 2009-04-22
CA2415990C (en) 2009-07-07
FI971998A (fi) 1997-05-09
CA2415990A1 (en) 1996-05-23
HK1002285A1 (en) 1998-08-14
JP3158157B2 (ja) 2001-04-23
FI121117B (fi) 2010-07-15
ATE429246T1 (de) 2009-05-15
ATE542891T1 (de) 2012-02-15
DK0791055T3 (da) 2012-04-16
EP2290053A1 (en) 2011-03-02
WO1996015231A2 (en) 1996-05-23
WO1996015231A3 (en) 1996-08-01
EP1213030A1 (en) 2002-06-12
EP0791055A1 (en) 1997-08-27
CA2205015A1 (en) 1996-05-23
CA2205015C (en) 2003-04-08
ES2378409T3 (es) 2012-04-12
FI971998A0 (fi) 1997-05-09
DE69535940D1 (de) 2009-06-04
ES2323490T3 (es) 2009-07-17
EP0791055B1 (en) 2012-01-25
JPH10503093A (ja) 1998-03-24

Similar Documents

Publication Publication Date Title
DK1213030T3 (da) Fremgangsmåde til fremstilling af biologiske produkter i protein-fri kultur
NO975434L (no) Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner
ATE353370T1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
GEP20084431B (en) Papilloma virus vaccine
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
DK0891420T4 (da) Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus
DK0702085T4 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
DK1108787T3 (da) Fremstilling af vacciner
ATE384785T1 (de) Herstellung von viren, virusisolaten, und impfstoffen
DK0480949T3 (da) Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse
ES2541540T3 (es) Métodos para generar preparados exentos de helper de alto título de vectores de AAV recombinantes liberados
NO20032097D0 (no) Gj¶ravledet vaksine mot IPNV
ATE453708T1 (de) Impfstoff gegen west nile virus
ATE486124T1 (de) Keratinozyten-kulturverfahren und verwendung davon
DE69535716D1 (de) Methode für die Produktion von multivalenten Influenza Hämagglutinin Vakzinen
EP2374894A3 (en) A method for producing influenza hemagglutinin multivalent vaccines
DE69021879T2 (de) Verfahren zur herstellung von impfstoffen gegen rna-virus.